Liquid Biopsy in Glioblastoma

Ronvaux, Lorian; Riva, Mattéo; Coosemans, An; Herzog, Mariëlle; Rommelaere, Guillaume; Donis, Nathalie; D’Hondt, Lionel; Douxfils, Jonathan

doi:10.3390/cancers14143394

Cited by 24 publications

(17 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As numerous mutations and epigenetic alterations collaborating with the IL-7 receptor signaling pathway have been identified in acute lymphoblastic leukemia, the IL-7 receptor interactome may also be of interest for advancing new treatment development in GBM [ 35 ]. Monitoring effectiveness of newer therapeutic interventions will also be of key importance, and may involve the inclusion of well-characterized biomarkers for liquid biopsy in addition to more traditional clinical and paraclinical measures [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma

et al. 2022

View full text Add to dashboard Cite

Background: Immune evasion in glioblastoma (GBM) shields cancer cells from cytotoxic immune response. Methods: We investigated CpG methylation in promoters, genes, and pathways in 22 pairs of formalin-fixed paraffin-embedded sequential (FFPE) GBM using restricted resolution bisulfite sequencing (RRBS) and bioinformatic analyses. Results: Gene ontology revealed hypermethylation in elements of the innate and adaptive immune system when recurrent GBM samples (GBMrec) were compared to control (CG) and primary GBM samples (GBMprim). Higher methylation levels of the IL-7 signaling pathway and response to IL-7 were found in GBMrec suggesting a progressive blockade of the IL-7 driven T cell response in sequential GBM. Analyses of the Cancer Genome Atlas array-based data confirmed hypermethylation of the IL-7 pathway in recurrent compared with primary GBM. We also quantified DNA CpG methylation in promoter and gene regions of the IL-7 ligand and IL-7 α-receptor subunit in individual samples of a large RRBS-based sequential cohort of GBM in a Viennese database and found significantly higher methylation levels in the IL-7 receptor α-subunit in GBMrec compared with GBMprim. Conclusions: This study revealed the progressive suppression of the IL-7 receptor-mediated pathway as a means of immune evasion by GBM and thereby highlighted it as a new treatment target.

show abstract

Section: Discussionmentioning

confidence: 99%

Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Among the three strategies mentioned, nano-/microscale MBs are the most extensively utilized for CTC isolation. 100,101 By incorporating specific recognition molecules onto the surface of MBs, they can rapidly bind to target cells and be easily separated from other cells using magnetic fields. Depending on the choice of recognition molecules, MBs can be employed for positive CTC capture 99 or negative isolation of blood cells.…”

Section: Topological Structurementioning

confidence: 99%

Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision‐making

Bao,

Min,

et al. 2023

Interdisciplinary Medicine

View full text Add to dashboard Cite

Liquid biopsy has emerged as a promising avenue for non‐invasive and rapid retrieval of pathological information from patient body fluids. Over the years, liquid biopsy has garnered significant attention for clinically treating cancer by selecting appropriate biomarkers such as circulating tumor cells (CTCs) and extracellular vesicles (EVs). Further integration of advanced technologies has facilitated the efficient capture of biomarkers for liquid biopsy, revolutionizing clinical decision‐making in the multiple processes and stages of cancer patients. Underscoring the intersection of different disciplines, this review provides a holistic summary of recent breakthroughs specifically designed for the capture and application of distinctive biomarkers to blend real‐world clinical decision‐making with material science. Firstly, we focus on the main principles of liquid biopsy and recent technologies that facilitate the capture and release of biomarkers (e.g., CTCs and EVs), leveraging their physicochemical properties. Then, the clinical applications of biomarkers are summarized, highlighting their potential for providing comprehensive clinical information. Later, the incorporation of machine learning is also emphasized for enhancing clinical applications and enabling deeper insights in the design of next‐generation platforms for specific biomarker isolation. Finally, future opportunities for clinical decision‐making are explored by combining advanced nanotechnologies and artificial intelligence, thereby offering inconceivable possibilities for improving patient care.

show abstract

“…Within the last 20 years, various methods were developed and applied which can be summarized with the term "liquid biopsy" (Figure 1) [39][40][41][42][43][44][45][46]. Basically, tumor cells or tumor derived nucleic acids, proteins, or EV can be detected in bodily fluids, which are repeatedly accessible and at a lower risk compared to tissue biopsy.…”

Section: Liquid Biopsymentioning

confidence: 99%

Liquid biopsy and glioblastoma

Eibl

Schneemann

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on neuroimaging techniques followed by histopathological and molecular analysis of resected or biopsied tissue. A recent paradigm shift in diagnostics ranks the molecular analysis of tissue samples as the new gold standard over classical histopathology, thus correlating better with the biological behavior of glioblastoma and clinical prediction, especially when a tumor lacks the typical hallmarks for glioblastoma. Liquid biopsy aims to detect and quantify tumor-derived content, such as nucleic acids (DNA/RNA), circulating tumor cells (CTCs), or extracellular vesicles (EVs) in biofluids, mainly blood, cerebrospinal fluid (CSF), or urine. Liquid biopsy has the potential to overcome the limitations of both neuroimaging and tissue-based methods to identify early recurrence and to differentiate tumor progression from pseudoprogression, without the risks of repeated surgical biopsies. This review highlights the origins and time-frame of liquid biopsy in glioblastoma and points to recent developments, limitations, and challenges of adding liquid biopsy to support the clinical management of glioblastoma patients.

show abstract

Liquid Biopsy in Glioblastoma

Cited by 24 publications

References 115 publications

Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma

Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma

Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision‐making

Liquid biopsy and glioblastoma

Contact Info

Product

Resources

About